- Home
- FBIO vs HURA Comparison
FBIO vs HURA Comparison
Compare FBIO & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FBIO | HURA |
|---|---|---|
| Founded | 2006 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.9M | 131.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FBIO | HURA |
|---|---|---|
| Price | $3.41 | $0.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $16.50 | $10.00 |
| AVG Volume (30 Days) | ★ 1.2M | 306.4K |
| Earning Date | 11-14-2025 | 02-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $62,303,000.00 | N/A |
| Revenue This Year | $29.71 | N/A |
| Revenue Next Year | $49.34 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.33 | $0.66 |
| 52 Week High | $4.53 | $5.27 |
Technical Indicators
Market Signals| Indicator | FBIO | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 45.34 | 27.79 |
| Support Level | $3.33 | $0.68 |
| Resistance Level | $3.60 | $0.73 |
| Average True Range (ATR) | 0.32 | 0.06 |
| MACD | -0.11 | 0.03 |
| Stochastic Oscillator | 12.11 | 9.03 |
Price Performance
Historical ComparisonAbout FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.